GlassScriptPhysician profile
Neil Hockstein
NPI 1831131317
$2,121.61
in general payments reported to CMS, 2019-2025
27 companies · $974 in 2025
The $974 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $48.99 · 2021: $106 · 2022: $199 · 2023: $238 · 2024: $418 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576 · Education: $52.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.03 |
| Education | $52.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $371.42 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Biocryst US Sales Co., LLC | $252.31 | 2022-2025 | Orladeyo |
| Genentech USA, INC. | $206.27 | 2024-2025 | Xolair |
| Medtronic, INC. | $164.66 | 2025 | Propel |
| Glaxosmithkline, LLC. | $155.18 | 2023-2025 | Nucala |
| Genzyme Corporation | $107.48 | 2020-2025 | |
| Integra Lifesciences Corporation | $101.78 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $92.45 | 2025 | Neffy |
| Pharming Healthcare, INC. | $71.18 | 2023-2024 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $69.65 | 2021-2024 | Takhzyro |
| Optinose US, INC. | $69.25 | 2019-2025 | |
| Abbvie INC. | $65.51 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $59.97 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $52.99 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $41.39 | 2021-2025 | Fasenra, Tezspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $40.45 | 2025 | |
| Acclarent, INC | $32.64 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $23.81 | 2021 | |
| Aerin Medical INC. | $21.30 | 2023 | |
| Lilly USA, LLC | $19.50 | 2025 | Zepbound |
| Ionis Pharmaceuticals, INC. | $17.64 | 2025 | |
| Kaleo, INC. | $16.10 | 2021 | |
| Gc Biopharma USA, INC. | $15.15 | 2025 | Alyglo |
| Stryker Corporation | $14.40 | 2022 | |
| Upsher-Smith Laboratories LLC | $13.31 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.19 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Hockstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.